Stayble Therapeutics appoints Lago Kapital AB as liquidity provider

Stayble Therapeutics AB (“Stayble” or “the Company”) has entered into a liquidity providing agreement with Lago Kapital AB. Stayble has terminated its existing liquidity providing agreement with Mangold Fondkommission AB. The liquidity providing agreement with Lago Kapital AB will be effective starting on May 9th, 2022.  

Lago Kapital AB will provide liquidity according to Nasdaq Stockholm rules set-out for liquidity providing. The intention is to promote liquidity in the share. The agreement will be in force initially for a fixed term of six (6) months and thereafter until further notice with a notice period of one (1) calendar month.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail ca@skmg.se